Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equine Nicotinamide Phosphoribosyltransferase (NAMPT) ELISA Kit-Sandwich

Cat. No.EK12F922

Product TypeAnimal Immunoassay Kits

Size

Product Overview

BioVenic Equine Nicotinamide Phosphoribosyltransferase (NAMPT) ELISA Kit-Sandwich is designed for the quantitative determination of Equine Nicotinamide Phosphoribosyltransferase (NAMPT) in serum, plasma, tissue homogenate, cell culture supernatant, cell extract, and other biological fluids using a Sandwich ELISA method. For research use only.

Specifications

Assay Type ELISA-Sandwich
Specificity The assay kit is specific for Equine NAMPT.
Target Species Equine
Species Reactivity Equine
Detection Range 0.156-10 ng/mL
Sensitivity 0.094 ng/mL
Reproducibility Intra-Assay: CV < 10%; Inter-Assay: CV < 10%
Assay Time Around 270 min
Sample Requirement Serum, plasma, tissue homogenate, cell culture supernatant, cell extract, and other biological fluids.

Target Information

Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B-cell colony-enhancing factor 1 (PBEF1) or visfatin (for its extracellular form), is an enzyme encoded by the NAMPT gene in horses. NAMPT catalyzes the synthesis of nicotinamide mononucleotide (NMN) from nicotinamide (NAM) and PRPP (in the presence of ATP). NAMPT has been shown to be secreted by cells and may act as a cytokine-like protein.

Target/Biomarker Equine NAMPT
Target Synonym Visfatin; nicotinamide phosphoribosyltransferase; NAMPT; PBEF1
Gene ID 100059684
UniProt ID F6S8Z5

Shipping and Storage

This product is shipped with gel ice packs. It is recommended to store at 2-8 °C (Up to 6 months).

Documents

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

  1. Galli, U. et al. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy. Frontiers in pharmacology. 2020, 11: 656.
Inquiry Basket